Lexicon Pharmaceuticals LXRX Accounts payable and other current liabilities
Accounts payable and other current liabilities at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's accounts payable and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's accounts payable and other current liabilities?
- Lexicon Pharmaceuticals (LXRX) reported accounts payable and other current liabilities of -$6.9M in Q1 2026.
- How has Lexicon Pharmaceuticals's accounts payable and other current liabilities changed year-over-year?
- Lexicon Pharmaceuticals's accounts payable and other current liabilities increased by 68.2% year-over-year, from -$21.69M to -$6.9M.
- What is the long-term trend for Lexicon Pharmaceuticals's accounts payable and other current liabilities?
- Over 2 years (2021 to 2024), Lexicon Pharmaceuticals's accounts payable and other current liabilities has grown at a -2.1% compound annual growth rate (CAGR), from -$15.43M to $14.8M.
- What does accounts payable and other current liabilities mean?
- This represents the net change in obligations owed to suppliers and other service providers for goods and services received but not yet paid. An increase serves as a source of operating cash flow, effectively acting as interest-free financing from vendors. It is a vital metric for evaluating the company's short-term liquidity and vendor payment strategy.